NCT06960707RecruitingPhase 3
Two Versus One Week Breast Radiotherapy (RT)
Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 28 Apr 2025
- Start date
- 29 Apr 2025
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Childhood cancers
- NCT number
- NCT06960707
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 400
- From 29 Apr 2025 to the primary completion date, 31 Dec 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiation therapy to the ipsilateral breast.
- \>90 days from last surgery, unless s/p adjuvant chemotherapy.
- \>60 days from last chemotherapy.
Other illness
- Male breast cancer.
- Ongoing treatment for severe autoimmune disease.
Who the study is looking for
- Women status post segmental mastectomy.
- If unilateral, pT1-2 breast cancer excised with negative margins.
- If bilateral, pT1-2 breast cancer excised with negative margins AND/OR pTis excised with negative margins.
- Clinically N0 (cN0 as determined by ultrasound/SOUND criteria) or pN0-1 or Nx or sentinel node negative.
- Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).
- Women with previous contralateral treated breast cancer can be enrolled in the trial.
Sex: Female · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brooklyn Methodist Hospital Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| New York Presbyterian-Weill Cornell Medical College Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| New York - Presbyterian Hospital Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.